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1. Introduction
Undoubtedly, a broad range of beneficial pharmaceutical agents available today is one of the
greatest scientific achievements. In recent years, numerous chemical and pharmaceutical
researches have been led to the production of a vast number of new potential drug candidates.
However, many of these new compounds are in a biopharmaceutical classification of low
solubility keeping drug dissolution rate as the limiting step for absorption of these drugs [1].
Many efforts are being performed to reformulation of present drugs to solve problems such
as low solubility, dissolution, bioavailability, flowability, compressibility, dosing problem,
stability and toxicity. Appropriate drug dissolution rate is necessary for attaining proper oral
drug therapy. The bioavailability of orally administrated drugs depends on their absorption
from the gastrointestinal (GI) tract [2]. In this rout of administration, poorly water soluble
drugs show low bioavailability because of their low solubility in GI media. The rate limiting
step in the absorption of these drugs is the dissolution rate of them in the GI fluids rather than
their diffusion through the GI membrane [3]. There are several techniques have been used for
enhancing dissolution rate of these drugs such as: physical and chemical modification,
preparing solid dispersion, complexation, solubilization, liquisolid technique, changing in
crystal habit and so on [4].
As we know, certain kinds of drugs might be existed in a variety of solid-state forms, including
polymorphs, solvates, hydrates, salts, cocrystals and amorphous solids. Then, selection of the
proper form of the drug would be severely important to a drug development processes.
Crystallization of a drug is an important thermophysical process in pharmaceutics that a drug
molecule precipitates in the medium due to supersaturation [5]. In general, crystallization may
be defined as the phenomena in which a solid compound precipitates from a saturated solution
(through cooling or evaporation) in the form of crystals [6]. Enhancement of dissolution rates
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of water insoluble drugs (Sulfathiazole, Prednisone and Chloramphenicol) by crystallization
has been investigated by Chiou et al in 1976 [7].
According to numerous papers, crystal habit can be modified by recrystallizing the drug. This
process can affect the physical and physicochemical properties. Variation in crystalline habit
is one of the proceeding trends in order to increasing the solubility, dissolution rate and
bioavailability of the poorly soluble drugs [8]. This process could potentially be utilized to a
wide range of drugs with different crystalline forms. Different crystals show different disso‐
lution rates and then different biological responses. Therefore the modification of crystal
properties should affect the bulk dissolution rate. Burt and Nickel (1979) by using the single
crystal dissolution method demonstrated that the different forms of the same crystals prove
different dissolve rates. Habit modification normally occurs when the environments of
growing crystals have effects on its external shape without changing its internal structure [9].
Kobayashi et al (2000) reported different dissolution rates for carbamazepine, where the
dihydrate form of the drug in simulated fluids (pH 1.2) had notably slower dissolution rates
than the anhydrous forms (forms I and III). Due to the rapid conversion of metastable
polymorph (form III) to the dehydrate form, this polymorph showed greatest rates of disso‐
lution at the initial stages but reductions at later time [10].
2. Dissolution rate of drug
As previously mentioned, the dissolution and release rate of a drug molecule are essential to
identification of drug characterization. The drug dissolution rate is an amount of a solid dosage
form that goes into solution in a certain amount of time. In the dissolution test, the drug
solubility is the main parameter that affects the rate of dissolution [11]. The poor dissolution
rates of poorly water soluble drugs are still a challenge in the pharmaceutical industry [12,
13]. The absorption rate of a poorly water soluble drug in an orally administered solid dosage
form is controlled by its dissolution rate in the fluid present at the absorption site and the
dissolution rate is often the rate-determining step in its absorption [14].
The size and shape have very important role in the separation process which will in turn affect
the yield and quality of the resulting fractions during the crystallization process [15]. Crystal
habit influences particle orientation, therefore can modify the flowability, packing, compati‐
bility, syringability, physical stability and dissolution profile of a drug molecule. For example,
it has been showed that symmetrically shaped crystals of Ibuprofen have better compaction
and flow properties than needle shaped crystals [16]. Therefore optimization of crystal
properties is an alternative method for modifying the dissolution properties of drugs and
therefore bioavailability of them [17].
There are many various factors that affect the dissolution rate of a drug substance. Some of
these factors include: concentration of the drug solution, size and surface area of the drug
substance, any movement or stirring, temperature, nature and type of drug matter and the
mass or volume of the drug [8]. By breaking a drug into smaller pieces, its surface area is
increased. When particle becomes smaller, because of greater interaction with the solvent, the
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solubility will be increased [18]. According to Noyes-Whitney equation, when particle size is
reduced, the total effective surface area is increased and thereby the dissolution rate is
enhanced. Indeed, when the total surface area of the drug particles is increased, the drug
dissolves more rapidly because the action takes place only at the surface of each particle and
then increases its dissolution rate [19-21]. Rising of temperature for liquids and solid solutes,
not only increases the amount of the dissolving solute but also can enhanced the dissolving
rate [22]. When the amount of solute in the solution is low, dissolution occurs relatively rapidly.
In the point that no solute can be dissolved, dissolution takes place more slowly. In the case
of liquid and solid solutes, stirring leads to fresh portions of the solvent in contact with the
solute, then the increased dissolution rate was obtained [23].
So far many techniques have been used to increase the solubility and therefore the dissolution
rate of poorly water soluble drugs. Methods such as cosolvency and microemulsion techniques
[24-27], crystal habit modification, complexation [28-31], formulation in proper salt form [32,
33], preparation of solid dispersion [8, 34-39], liquisolid technique [19, 40-44] and particle size
reduction [45-48] are some of these techniques. There are several disadvantages in the use of
each technique. For example, the salt formation process is complex procedure and the
dissolution enhancement is not always predictable in this process. Furthermore, this method
is not possible for neutral compounds [49]. As another example, solubilization techniques
normally show poor stability and insufficient acceptability of patients [50]. For choosing a
suitable technique for a certain drug, some certain aspects such as the properties of drug, nature
of excipients and nature of dosage form should be considered [51]. Crystal habit of a solid
stated form can be modified by recrystallizing process. Then this process can affect the physical
and physicochemical properties such as the melting point, solubility, true density, dissolution
profile, flowability and tabletability [52].
3. Recrystallization of drugs
Most active pharmaceutical ingredients are manufactured in the crystalline form for their
chemical stability during transportation, packaging and storage. Recrystallization is the simple
and inexpensive method for purifying solid organic materials whereby a crystalline form of a
compound may be obtained from other solid-state forms of the same substance [53]. In the
pharmaceutics, recrystallization is the process most often applied for the purification of solid
active pharmaceutical ingredients (APIs) [54]. Indeed, production of another crystalline form
as well as purification are the two main aspects in the recrystallization process of drugs.
Generally, a hot saturated solution of the drug is prepared using a solvent with appropriate
boiling point and then the solution is cooled and a new crystalline form of the drug is separated
[53]. This process occurs due to the lower solubility of new crystalline form of the drug in the
relevant solvent at lower temperatures. The recrystallization process of a drug has been
schematically illustrated in figure 1.
Recrystallization of the drug in a suitable solvent leading to altering physical and chemical
properties of obtained particles. These properties are consist of the wettability, melting point,
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solubility, dissolution rate, flowability and compactibility [55]. There are some reports about
the recrystallization process and its effects on different properties of drugs [56-58]. This
technique has been used for huge or small quantities of materials and very effective and
efficient results were obtained.
Various factors including thermodynamic (e.g., solubility, solid-liquid interfacial tension,
solvent activity, temperature, etc.), kinetic (e.g., supersaturation, molecular mobility, meta-
stable zone width), and molecular recognition (hydrogen bonds, non-covalent bonds, molec‐
ular networks) may influence on the rate and mechanisms by which crystals are formed from
liquid solutions [59, 60]. The driving force for crystallization is supersaturation. Supersatura‐
tion can be created by increasing the solute concentration (solvent evaporation) or decreasing
the solute solubility (e.g., temperature change, antisolvent addition, pH change, salting out)
[61]. The next step is the formation of macroscopic crystals from stable nuclei, known as crystal
growth. This step is controlled by internal (crystal structure) and external factors (temperature,
impurities, supersaturation, solvent type) and determines the particle morphology [62].
It was shown that changing of crystal habit by recrystallization has significant effect on
dissolution rate. Nogami and Kato found that the recrystallized thin crystal of the aspirin
shows better dissolution and excretion behavior compare to the commercial aspirin [63].
Valsartan (VAL) is a potent, highly selective and orally active antihypertensive drug with
sparingly solubility in aqueous media (especially in gastric fluids). Therefore its absorption is
limited by its dissolution rate. Nalluri et al. prepared and investigated the recrystallized form
of this drug. According to their results (evidenced by the DSC and powder X-RD studies), by
applying of the recrystallization technique, VAL can be transposed into either amorphous
phases or amorphous dispersions. The recrystallized VAL exhibited improved aqueous
solubility and dissolution properties and potentially therapeutic efficacy compared to an
untreated drug [52].
Figure 1. Schematic illustration of the drug recrystallization process.
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Nokhodchi et al. recrystallized phenytoin in ethanol and acetone. According to their results,
needle-like and rhombic crystal habits exhibit different dissolution rates. They suggested that
the differences in dissolution rates for phenytoin were related with the surface area of various
crystals with different shapes [64].
Carbamazepine is a poorly water soluble drug and its absorption may be unpredictable. This
drug is applied as first line monotherapy for seizures in elderly patients. Proven efficacy and
less cost are two major advantages of carbamazepine. Mahalaxmi et al. recrystallized carba‐
mazepine by using two solvents and at different cooling conditions. Their outcomes showed
improved dissolution behavior of the treated drug [65].
Adhiyaman et al. reported different properties of dipyridamole crystals that prepared by the
recrystallization process. Dipyridamole is a critical antiplatelet and peripheral vasodilator
drug that has poor water solubility and then bioavailability, which limits its effectiveness in
clinical  tries.  Their  results  showed  that  the  prepared  crystals  of  dipyridamole  under
optimized conditions, significantly improved the dissolution rate of the drug compared to
untreated one [66].
Applying of solvents or high temperatures did not modify the crystalline form of ketoconazole.
It was reported that adjusting of growth of crystal faces can affect on the physicochemical
properties of the ketoconazole crystals. It was demonstrated that habit modification and
different degrees of crystallinity are significant parameters in the enhancement of the disso‐
lution rate [67].
3.1. Recrystallization steps
Choosing a proper solvent is the first step of the recrystallization process. After selection of a
proper solvent, an impure compound is dissolved in the minimum amount of a hot solvent.
Then solution is decolorized with activated charcoal (if needed) and any insoluble material is
filtered off. If the crystal formation process occurs too rapidly, impurities may become trapped
in the crystals. Slowly cooling of the resulting solution to induce crystallization is the next step.
Finally the crystals are collected, washed and dried. Figure 2 shows steps of the recrystalliza‐
tion process [9, 66, 68].
3.1.1. Choosing a proper solvent
The most important feature of the recrystallization technique is the selection of the solvent.
There are two main facts in purification of solid organic materials by the recrystallization
method: different solids have different solubilities in a given solvent and most solids are more
soluble in hot than in cold solvents [69, 70].
Numerous solvents are employed for recrystallization of drug compounds. Selection of the
recrystallization solvent should be performed on a case-by-case basis [9, 68]. This is due to the
variant solubility of different organic compounds in these solvents. It is clear that, at the first,
the material should be introduced into solution and then can able to come back out of solution.
Choosing the appropriate solvent is very important in recrystallization, because it leads to
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increasing our yield of product [9, 25, 68]. This selected solvent should have a lower boiling
point than the melting point of the solid that being recrystallized. Furthermore, the drug should
be soluble in the boiling solvent but have poor solubility in the same solvent after cooling [25,
64].
3.1.2. Melting point of drug and solvent
A melting point is employed to identify a substance and to get an indication of its purity. The
melting point of a solid is the temperature at which the vapor pressure of the solid phase
becomes equal to the vapor pressure of the liquid phase. Purity of a recrystallized drug is
evaluated by observing its color and by measuring its melting point range. According to
literature, the boiling point of the recrystallization solvent should be lower than the melting
point of the compound to be recrystallized. If it is higher than the melting point of drug, the
drug will “oil out”, the process in which a drug is insoluble in a solution at a temperature above
its melting point [9, 66, 68].
3.2. Common procedures for recrystallization
Different polymorphs of active pharmaceutical ingredients can be obtained though recrystal‐
lization processes based on solvents, solid-state transitions and vapor deposition [54].
In the controlled kinetic or thermodynamic conditions, crystallization of drug polymorphs can
be performed from a solvent system. Supercritical fluid techniques are used for micronization
and recrystallization of different drugs. According to the reports, modification of solid state
Figure 2. Steps of the recrystallization process.
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characteristics, such as crystal habit, crystallinity and polymorphism, has been successfully
achieved through recrystallization of drug particles using various supercritical antisolvent
(SAS) processes [70, 71]. This technology by using carbon dioxide gas is able to modify the
solid state properties of drugs, such as characteristics of particles (size, shape, surface, crystal
structure and morphology), crystallinity and polymorphism leading to affecting their disso‐
lution rate and bioavailability [72]. The supercritical anti solvent technique is based on injection
of an organic solution (containing of drug crystals) into supercritical carbon dioxide. During
of the mixing, supercritical CO2 is quickly dissolved in the organic solution and leads to the
precipitation of solutes (drug) by an antisolvent effect. Then supercritical CO2 efficiently
extracts the organic solvent, leads to achieving completely solvent-free products [71]. Figure
3 shows recrystallization of a drug by using the supercritical antisolvent (SAS) process
schematically.
Figure 3. Recrystallization by using the supercritical antisolvent (SAS) process. A) Drug solution in good solvent; B)
Peristaltic pump; C) Spraying gun for drug solution; D) Chamber with saturated CO2 gas
Some drugs have also been recrystallized by the spherical agglomeration technique in order
to modify their dissolution properties. For poorly water soluble drugs, a water immiscible
organic solvent can act as an external phase and a 20 % calcium chloride as a bridging liquid
[73]. The spherical crystallization is a particle size enlargement method that includes crystal‐
lization and agglomeration using bridging liquid [74]. Indeed, this method is a particle design
technique that crystallization and agglomeration can be performed simultaneously in one step
to transform crystals directly into the compacted spherical form [75, 76]. By using of this
method, direct tabletting of drug instead of further processing like mixing, granulation, sieving
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and drying is possible [73, 76, 77]. In 1986, Kawashima applied the spherical crystallization
method for size enlargement of drugs in the pharmaceutical field. Martino et al prepared
spherical propyphenazone crystals by the agglomeration recrystallization technique using a
three solvent system [78]. Figure 4 shows the mechanism of the recrystallized agglomerates
formation by the spherical agglomeration method.
Figure 4. Mechanism of the recrystallized agglomerates formation by the spherical agglomeration technique; A) Re‐
crystallization by addition of bridging liquid, B) Random coalescence, C) Enlarged spherical agglomerates.
The most commonly used spherical crystallization techniques are spherical agglomeration and
quasi-emulsion solvent diffusion. In both processes, a good solvent that dissolves the com‐
pound to be crystallized is used. A poor solvent (as an antisolvent) is used to generate the
required supersaturation [74, 77].
Polymorphs may also be generated through solid-state transition by recrystallization of
metastable polymorphs and amorphous forms, or through desolvation of solvates (including
hydrates) [60]. Physical vapor deposition (PVD) method is an atomistic deposition procedure
in which material is vaporized from a solid or liquid source in the form of atoms or molecules
and transported in the form of vapor through a low pressure environment to the substrate
where it condenses [60, 79].
4. Mechanism of recrystallization that effects on dissolution rate
In the nature, crystals can be categorized into seven crystal systems with various properties.
Each of these crystal systems has differences in the relative sizes of their faces as well. This
variation is called crystal habit modifications. In fact the morphology of a crystal depends on
the growth rates of the different faces of it. Fast growing faces have little or no effect on the
growth form while slow growing faces have more influence. Environmental conditions and
structure and defects of crystal governed the growth of a given face [80]. The interaction of the
solvent at the different crystal solution interfaces may cause to modified roundness of growing
crystal faces (or edges), changes in crystal growth kinetics and enhancement or inhibition of
crystal growth at certain faces [54]. Figure 5 shows the crystal habits arising from growth
inhibition at crystal faces.
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Figure 5. Crystal habits arising from growth inhibition at crystal faces; A) Growth equal in all dimensions, B) Growth
inhibited in one dimension, C) Growth inhibited in two dimensions.
In pharmaceutical manufacturing, a crystal habit of a drug molecule is an important charac‐
teristic. Different crystals have different planes, specific surface and free surface energy.
Therefore they show different physicochemical properties such as dissolution rate, flowability
and compressibility [68]. The existence of the drug structure in various crystalline shape
influence on the bioavailability and biological efficacy of a drug [66]. The crystalline form that
has the improved dissolution rate and solubility is useful for developing the efficient phar‐
maceutical product of drugs [68, 81].
The primary mechanism of recrystallization is the long-range motion of grain boundaries that
removes dislocations from the material [82]. According to numerous reports wettability and
consequent dissolution rate of different crystalline forms of drugs could be determined by
exposure of diverse crystal faces [83]. The constituent molecules of a crystalline material are
part of an orderly three-dimensional structure [84]. Depending on the crystallization condi‐
tions, these molecules arrange in different forms. This crystalline form of material is known as
polymorphic and each of its crystal ordering is called a polymorph. Indeed, the polymorphs
are substances with the same chemical composition but presenting different crystalline forms
[85]. Different crystalline forms include various crystallographic systems, lattice parameters
and position of the atoms in the elementary cell [86]. Under different conditions, a crystalline
drug is crystallized into different polymorphic forms. Polymorphs of a substance show
different physical properties, such as solubility and dissolution properties. In fact, crystals with
higher free energy show higher solubility. Since the molecules in crystals with high energy
have weaker solid-solid interactions compared to crystals with lower energy, they exhibit
higher affinity for the solvent in the surroundings [87]. Figure 6 shows the probable conse‐
quences of a different crystal form in solubility.
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Figure 6. Probable consequences of a different crystal form in solubility
Figure 7 show formation of different crystals following by recrystallization of the initial
crystalline form schematically. First, the reaction between solid and solvent breaks the solid
crystalline substances (opens the amorphous lattice for amorphous substances). This creates
cavities in the solvent (known as phase change) and, hence, molecules of solid become
molecules of solute. Then solute molecules recrystallized into another crystalline form(s) [88].
Figure 7. First the reaction between solid and solvent breaks the solid crystal for crystalline substances (opens the
amorphous lattice for amorphous substances). This creates cavities in the solvent (known as phase change) and, hence,
molecules of solid become molecules of solute. Then solute molecules recrystallized into another crystalline form(s).
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Additional information is necessary for control of the nucleation and crystal growth. Dunitz
and Bernstein have evaluated the disappearing polymorphs by considering various examples.
They state that ''once a particular polymorph has been obtained, it is always possible to obtain
it again; it is only a matter of finding the right experimental conditions'' [89].
5. Effect of excipients and additives on the recrystallization process
Crystal morphology engineering is a useful tool for improving tabletting efficiency of phar‐
maceutical solids. Pharmaceutically accepted excipients can be applied as crystal habit
modifiers to overcome the toxicity and/or environmental concerns [90]. Excipients and
polymers have a major role to prepare the recrystallized form of a drug. The difference in the
physicochemical properties of the drug molecules and the excipient is the main factor in
selection of a solvent system for the recrystallization process. The presence of additives such
as the polymeric material and surface active agents can influence molecular aggregation
during crystallization. Viscosity of the medium and surface tension are reduced by the
surfactants that affect the nucleation process. The presence of these additives in the spherical
agglomeration process may also reduce the processing time and improves the bioavailability
and the micrometric properties of drug [91].
Various polymers like hydroxy propyl methylcellulose (HPMC), poly ethylene glycol (PEG),
ethyl cellulose (EC) and poly vinyl pyruvate (PVP) can be used to improve poor compressi‐
bility and handling qualities of pure drugs by crystallization techniques [92]. This improves
the micromeritic and drug release properties of the crystals as well.
Crystallization is inhibited by some of the polymers such as methylcellulose, Hyroxypropyl
methyl celluose (HPMC), Polyvinylpyrrolidone (PVP). Among these, PVP has been found to
be the most effective in inhibiting crystallization of drugs. These antinucleant polymers are
incompatible in both size and size of the host molecules of the growing crystals surface. Then,
their incorporation into the lattice alters growth characteristics of the host molecules [93].
Recrystallization of the amorphous drug may be avoided by entry of stabilizing hydrophilic
excipients in the composition. Indeed, stabilizing excipients are prevented recrystallization of
amorphous drug particles by steric hindrance and/or the formation of hydrogen bond with
drug molecules [94]. As a noticeable point, the stabilizing excipients should be hydrophilic for
improving the wetting properties of drug particles and these hydrophilic excipients should
not be hygroscopic as well.
6. Methods for characterization of crystals
There are different analytical methods and techniques for characterization of various proper‐
ties of crystals and therefore efficiency of the recrystallization procedure. Measuring of size,
crystal size distribution and surface microtopographic observations can help to prediction of
growth mechanisms of crystal faces under different conditions. Monitoring the surface
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topography during crystal growth can display events that are not evident from morphology
studies. Some characterization techniques of the crystals are collected in table 1.
Technique(s) Characteristic(s)
Sieve analysis, laser diffraction, and computerized image
analysis. Size and size distribution of crystals [95].
Optical microscope Size, morphology and shape of crystals [96].
Scanning electron microscopy Size, surface topography, polymorphism and crystal habit[95].
X-ray powder diffraction
It is important for establishing batch-to-batch
reproducibility of a crystalline form.
The type of crystal can be determined by using this
technique. An amorphous form does not form a special
pattern [97].
Fourier Transform Infrared spectrometer (FTIR) It is much more beneficial for identifying between solvatesand anhydrous form [95].
Differential scanning calorimeter (DSC)
It can measure the heat loss or gain resulting from physical
or chemical changes within a sample. If a mixture of drugs
and polymer is crystallized together then variation in
properties of crystals can be evaluated with DSC [75].
Angle of repose, angle of spatula, angle of fall and Carr’s
index. Flowability [98].
Contact angle of water to the compressed crystals Wettability (As the contact angle is decreased the wettabilityis enhanced) [99].
By measuring the interfacial tension between the bridging
liquid and the continuous phase, contact angle and the ratio
of the volumes of the bridging liquid and solid particles.
The strength of the agglomerated crystals [78].
From the comparison of stress relaxations and elastic
recovery the compressibility of the spherical and single
crystals can be evaluated.
Compressibility [100].
Table 1. Characterization techniques of the crystals
Understanding the thermodynamic and kinetic behavior of the system is necessary for
developing of reliable processes. There are various techniques that can be informed us about
crystallization kinetics and growing mechanisms.
Various information can be obtained by using of an optical microscopy (inverted microscope);
studying of crystallization processes in situ, monitoring of the transformations in suspensions,
determination of transformation times, screening and characterization of additive/solvent
interactions with specific crystal faces, identification of nucleation mechanisms and measuring
the crystal growth rate [96]. Three latter mentioned points can be achieved by using an electron
microscopy and atomic force microscopy techniques as well. Monitoring of molecular
association processes that direct nucleation and crystal growth can be performed by Raman
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spectroscopy [95]. Spectrophotometry and chromatography techniques are applied for
measuring of the concentration of solute in solution and supersaturation process, and a
diffraction calorimetry spectroscopy for monitoring the solid phase composition of crystals
[101, 102].
7. Conclusion
The solubility, dissolution rate and crystal properties of a drug substance play a key role in
the pharmaceutical development, manufacturing and formulation. Low solubility of a certain
crystalline form of a drug leads to the low dissolution rate and bioavailability and therefore
reduced biological responses. Low solubility reduces also rates of drug clearances and then
increases the toxicity of the drug product. Drug crystals can be modified by the recrystallization
technique and this process can affect the physical and physicochemical properties such as
melting point, solubility, true density, dissolution profile, flowability and tabletability. The
recrystallization method is simple and inexpensive enough for scaling up to a commercial
level. This method has showed an efficient role in the increasing of the bioavailability of poorly
soluble drugs. Understanding the thermodynamic and kinetic behavior of the system is
necessary for the development of suitable recrystallization processes. Under controlled
conditions, recrystallization may lead to enhanced surface area and revelation of more polar
surface moieties, therefore cause to enhanced dissolution rate. Conversion to a more stable
polymorph, recrystallization of the amorphous material or reduced chemical stability are some
of the recrystallization problems in regard to solubility and dissolution rate of drugs.
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